Pila Pharma AB (PILA)

Currency in SEK
2.52
+0.02(+0.80%)
Closed·
PILA Scorecard
Full Analysis
Stock has taken a big hit over the last week
Unusual trading volume
Trading near 52-week Low
PILA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.332.58
52 wk Range
2.336.40
Key Statistics
Prev. Close
2.5
Open
2.4
Day's Range
2.33-2.58
52 wk Range
2.33-6.4
Volume
163.59K
Average Volume (3m)
66.95K
1-Year Change
-57.29%
Book Value / Share
0.19
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PILA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock has fared poorly over the last month

Pila Pharma AB News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

Pila Pharma AB Company Profile

Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is headquartered in Malmö, Sweden.

Employees
1
Market
Sweden

Pila Pharma AB Earnings Call Summary for Q4/2024

  • Pila Pharma's stock rose 5.18% to 3.67 SEK, with a 172.86% return over the past year despite high revenue multiples
  • Company ended 2024 with SEK 6.4M cash, aligning with burn forecasts; R&D expenses increased for XEND0501 obesity/diabetes treatment
  • Preparing for 30-40 patient Phase IIa trial; exploring partnerships with potential deals up to €700M
  • Focus on TRPV1 antagonist for obesity/diabetes; CEO notes unique position in market
  • Challenges include regulatory hurdles, market competition, and financial sustainability
Last Updated: 27/02/2025, 15:56
Read Full Transcript

Compare PILA to Peers and Sector

Metrics to compare
PILA
Peers
Sector
Relationship
P/E Ratio
−9.0x0.0x−0.5x
PEG Ratio
−1.540.000.00
Price/Book
19.2x0.0x2.6x
Price / LTM Sales
127.9x0.0x3.3x
Upside (Analyst Target)
-0.0%43.5%
Fair Value Upside
Unlock0.0%6.8%Unlock

Earnings

Latest Release
Mar 27, 2025
EPS / Forecast
-0.26 / --
Revenue / Forecast
106.89K / --
EPS Revisions
Last 90 days

PILA Income Statement

FAQ

What Stock Exchange Does Pila Pharma AB Trade On?

Pila Pharma AB is listed and trades on the Stockholm Stock Exchange stock exchange.

What Is the Stock Symbol for Pila Pharma AB?

The stock symbol for Pila Pharma AB is "PILA."

What Is the Pila Pharma AB Market Cap?

As of today, Pila Pharma AB market cap is 105.84M.

What Is Pila Pharma AB's Earnings Per Share (TTM)?

The Pila Pharma AB EPS (TTM) is -0.44.

From a Technical Analysis Perspective, Is PILA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Pila Pharma AB Stock Split?

Pila Pharma AB has split 0 times.

How Many Employees Does Pila Pharma AB Have?

Pila Pharma AB has 1 employees.

What is the current trading status of Pila Pharma AB (PILA)?

As of 09 Aug 2025, Pila Pharma AB (PILA) is trading at a price of 2.52, with a previous close of 2.50. The stock has fluctuated within a day range of 2.33 to 2.58, while its 52-week range spans from 2.33 to 6.40.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.